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Abstract
Studies have reported a sex bias in case fatalities ofCOVID-19 patients.Moreover, it is observed
that men have a higher risk of developing a severe form of the disease compared to women,
highlighting the importance of disaggregated data of male and female COVID-19 patients.
On the other hand, other factors (eg, hormonal levels and immune functions) also need to
be addressed due to the effects of sex differences on the outcomes of COVID-19 patients.
An insight into the underlying causes of sex differences in COVID-19 patients may provide
an opportunity for better care of the patients or prevention of the disease. The current study
reviews the reports concerning with the sex differences in COVID-19 patients. It is explained
how sex can affect angiotensin converting enzyme-2 (ACE2), that is a key component for the
pathogenesis of COVID-19, and summarized the gender differences in immune responses and
how sex hormones are involved in immune processes. Furthermore, the available data about the
impact of sex hormones on the immune functions of COVID-19 cases are looked into.
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Sex Differences and COVID-19
Several studies have shown that there is an association between the sex of COVID-19
patients and fatality rates, as well as critically-ill status. Studies in China, South Korea,
United States, and Italy have reported a similar trend of sex bias in fatality rates of
COVID-19 patients, representing that case fatality rates are higher in male patients than
in female patients.1-3 Noteworthy, the same findings have reported in the previous outbreaks
of coronaviruses, Severe Acute Respiratory Syndrome (SARS), and the Middle East
Respiratory Syndrome (MERS).4,5 Moreover, studies performed on mice have shown that
males are more susceptible to coronaviruses.6 The likelihood of death is reported to be 65%
higher in male patients with COVID-19 than in women. The World Health Organization
(WHO; Geneva, Switzerland) indicated that a lower percentage of women who are infected
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with the virus will die in comparison with men (1.7%/2.8%).
Another investigation also reported that less female patients
needed intensive care or died compared to male patients
(15%/32%).7 In 43 hospitalized patients, women were significantly
less prone to develop the severe form of the disease.8 Jin, et al8
expressed that male patients’ deaths in a population of 37 cases were
2.4-times that of female patients. Moreover, they concluded that
men’s worse outcomes and higher deaths compared to women is
not dependent on age.8 In a retrospective study of 168 confirmed
patients with COVID-19, deaths occurred in 12.8% of men
(n = 11/86); meanwhile, 7.3% of women died (n= 6/82).9 It is
observed that there are differences in laboratory parameters of
men and women, including neutrophil/lymphocyte ratio, hemato-
crit, hemoglobin, ferritin, alanine aminotransferase, aspartate ami-
notransferase, total bilirubin, C-reactive protein (CRP), blood urea
nitrogen, and creatinine (all P values <.05). Moreover, male
patients with comorbidities had a higher risk of developing a criti-
cally-ill status compared with men without comorbidities; whereas,
there was no such association in women.9 Evidence suggested that
female patients experienced some COVID-19 symptoms signifi-
cantly more thanmale patients, such as fatigue, anosmia, headache,
sore throat, and nasal obstruction.10 Moreover, some symptoms
were experienced significantly more by men than women, includ-
ing cough and fever. However, it is reported that there was no dif-
ference regarding disease duration between men and women.10
Borghesi, et al3 also reported that in COVID-19 patients aged
between 50 to 79 years old, men had a significantly higher score
of chest x-ray scoring system than women.
Besides the different effects of COVID-19 on the physical
status of men and women, studies have shown that the same goes
for mental health of people. Studies of general population indicated
that women present more mental disorders symptoms compared to
men during the COVID-19 pandemic, including signs of depres-
sion, anxiety, post-traumatic stress symptoms, and decreased sleep
quality.11,12 In the viewpoint of health care workers, evidence shows
that COVID-19 has affected the mental health of female medical
staff more than men.13 Altogether, this information highlights the
importance of disaggregated data of male and female COVID-19
patients. An insight into the underlying causes of sex differences in
COVID-19 patients may provide an opportunity for better care of
the patients or prevention of the disease. Additionally, attention
should be paid to other factors which are or may be related to
this sex bias in fatality rates of COVID-19 patients, including
hormonal levels, immune functions, comorbidities, and related
conditions, as well as gender-related factors, including lifestyle
and socioeconomic aspects.14
Possible Underlying Causes of Sex Differences in COVID-19
Patients
Sex Differences in Inflammatory Processes
Since X-chromosome encodes some genes related to immune
responses, women have a lower level of viral load and less inflam-
mation compared to men. Women’s immune cells activate more
than men, which is associated with the stimulation of toll-like
receptor-7 and interferon production. Besides, after infection with
viral agents, women produce lower levels of interleukin-6 (IL-6)
compared to men, which is associated with better longevity.15
Plasma concentration of testosterone, which decreases with age,
is reported to be reduced by some comorbidities, such as diabetes,
obesity, and obstructive sleep apnea.16 Evidence has shown that
these comorbidities are common in patients with COVID-19.
Investigations have indicated that agingmen have a reduced testos-
terone level, which is related to an elevated pro-inflammatory
condition.17 Besides, it is observed that testosterone therapy
leads to a reduction in IL-6, IL-1β, and tumor necrosis factor α
(TNF-α).18 Therefore, Pozzilli, et al19 proposed that through
the activation of cytokine storm, testosterone may be involved in
the progression of COVID-19. Androgen receptor (AR) is
involved in the regulation of both innate and adaptive immune
responses, including the macrophage and neutrophil recruitment
which is related to COVID-19.20-22 In mice infected with a
respiratory virus, estrogen receptor (ESR) signaling is reported
to increase the morbidity and mortality. While this observation
applies to both sexes, estrogen therapy has resulted in the suppres-
sion of inflammatory processes and reduction of virus titers in
animal models.23 Estrogen enhances immune responses and sub-
sequently, pathogens clearance occurs faster and vaccines will be
more effective. Contrary to estrogen, testosterone plays inhibitory
roles in immune processes, which is a possible explanation for
men’s higher susceptibility to infections.24 Thus, sex hormones’
alterations may cause some changes in the immune response to
pathogen, indicating the role of some other relevant conditions,
such as pregnancy and hormone therapies in COVID-19.14
In a cohort study of 31 male COVID-19 patients, data demon-
strated that patients who were transferred to intensive care unit
(ICU) or died in respiratory ICU (RICU) had lower amounts
of total testosterone (TT) and calculated free testosterone (cFT)
compared to patients who were transferred to internal medicine
unit or were at a stable condition in RICU.25 The TT and
cFT levels were negatively associated with some risk factors, includ-
ing lactic dehydrogenase, procalcitonin, and neutrophil count.
However, the levels of TT and cFT were positively associated with
the lymphocyte count. Furthermore, TT had a negative correlation
with the amounts of CRP and ferritin.25 Fagone, et al26 observed that
in age group of 40 to 60 years, the transcriptomic characteristics of
female lung tissue hasmore similarities toCOVID-19-induced char-
acteristics compared to male tissue. A possible explanation of the
lower incidence of COVID-19 in female patients could be the lower
threshold of acute immune response to COVID-19 in men com-
pared to women. The AR regulates two chemotactic factors, the
chemokine (C-X-C motif) ligand-1 (CXCL1) and chemokine
(C-C motif) ligand-20 (CCL20), which are encoded by COVID-
19-induced genes. The ESR1 regulates C3 and endothelin-1, which
are also encoded by COVID-19-induced genes.26 Fagone, et al26
suggested that while CXCL1 and CCL20 are involved in different
infections of coronavirus, response to these infections are occurred
by different agent in men and women. Moreover, it is shown higher
mortality rates in female mice with SARS coronavirus (SARS-CoV)
who were treated by the antagonist of ESR in comparison with their
counterparts who were treated with vehicle.27
Angiotensin-Converting Enzyme-2 (ACE2) Differences in Men
and Women
Angiotensin-converting enzyme-2 (ACE2) is an essential compo-
nent for the entrance of COVID-19 to the cells.28,29 Since ACE2
gene is located on X-chromosome, women have the potential to be
heterozygous regarding this enzyme while men are homozygous.7
To priming spike protein, COVID-19 also requires the transmem-
brane serine protease-2 (TMPRSS2).30,31 The TMPRSS2 is
the only critical protease for the pathogenesis and viral spread of
SARS-CoV.32 While TMPRSS2 gene transcription depends
on the activity of AR, there is no other promotor to do the same
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function in humans.33 It is suggested that testosterone may
lead to male predominance of severe infections (eg, COVID-19)
through modulating the expression of TMPRSS2.34 In the
other hand, TMPRSS2 is the most common gene involved in
primary prostate cancer, indicating that administering inhibitors
of TMPRSS2, which are currently used for prostate cancer, may
be helpful for treatment or prevention of COVID-19.33,35,36
The ACE2 may be cleaved by TMPRSS2, leading to an enhance-
ment in the entry of the virus.37 Interestingly, rebalancing of
ACE1/ACE2 or high levels of ACE2 possibly enhances the
COVID-19 outcomes in both males and females through reducing
thrombosis, inflammation, and death.7
ADAM metallopeptidase domain-17 (ADAM-17), which is a
disintegrin and metalloproteinase-17, leads to the soluble ACE2
(sACE2) and shedding of SARS-CoV through the cleavage of
myocardial ACE2 (mACE2).38,39 Evidence has revealed that both
sexes have the same levels of sACE2 up to the age of 12. However,
its levels increase in boys with their growth and women have a lower
level of sACE2 than men from the of 15.40 As evidenced by Sward,
et al,40 cases with higher sACE2 (men>women) may have a greater
risk of severe COVID-19. It is shown that ACE2 over-expression
has led to the severity of SARS-CoV disease in mice.41 Studies
also indicated that high activities of mACE2 and/or ADAM-17
may be involved in the severity of COVID-19.38,41 Contrary to
the globally observed data, female rats with higher expression of
ACE2 are reported to have poorer prognosis.7 Stelzig, et al6
reported that normal human bronchial epithelial (NHBE) cells
that were treated with 17β-estradiol (E2) had a lower expression
level of ACE2 messenger ribonucleic acid (mRNA) compared
with NHBE cells that were treated with the vehicle, ethanol.
Experimental animal studies have indicated that in kidney and
adipose tissue, E2 enhances the activity and expression of
ACE2.42 Noteworthy, precautions should be observed in testoster-
one therapy, especially in men with hypogonadism, due to the
recent evidence of venous thromboembolism in COVID-19
patients.42
Limitations
However, this study has some limitations. First of all, not all
published papers are in English, and thus had to be excluded from
this review. Another limitation that was faced was the inconsis-
tency of existing data from COVID-19 patients. Besides, a signifi-
cant number of studies concerning COVID-19 have not reported
the disaggregated data of men and women due to the urgent
need for rapid publications of the research. Furthermore, findings
in this area are limited and there are not many large-scale studies
reporting the sex differences in COVID-19 patients and the reason
for this difference. Thus, further studies are required to draw a
conclusion.
Conclusions
Studies of COVID-19 patients have shown that men have a higher
risk of developing to the severe form of the disease compared to
women. Moreover, case fatalities are higher in male patients than
female patients. Therefore, more attention should be paid to sex
as an important variable. By reviewing the literature about the
sex differences in COVID-19, it can be concluded that some
sex-related factors are involved in determining the patients’
outcomes. This study shows that different levels of ACE2 in
men and women, the effects of testosterone on ACE2 levels,
and the fact that the ACE2 gene is located on the X-chromosome
should not be ignored. Furthermore, the effects of sex on immune
responses and data available on the sex differences in COVID-19
patients and immune system are summarized. However, findings
in this area are limited and further studies are required to draw a
conclusion.
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